QuiaPEG Pharmaceuticals Holding AB (QUIA) - Total Liabilities
Based on the latest financial reports, QuiaPEG Pharmaceuticals Holding AB (QUIA) has total liabilities worth Skr8.81 Million SEK (≈ $947.88K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does QuiaPEG Pharmaceuticals Holding AB generate cash to assess how effectively this company generates cash.
QuiaPEG Pharmaceuticals Holding AB - Total Liabilities Trend (2008–2024)
This chart illustrates how QuiaPEG Pharmaceuticals Holding AB's total liabilities have evolved over time, based on quarterly financial data. Check QuiaPEG Pharmaceuticals Holding AB (QUIA) asset resilience to evaluate the company's liquid asset resilience ratio.
QuiaPEG Pharmaceuticals Holding AB Competitors by Total Liabilities
The table below lists competitors of QuiaPEG Pharmaceuticals Holding AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tasty Plc
LSE:TAST
|
UK | GBX36.13 Million |
|
IQ-AI LTD. LS -01
F:5Y1
|
Germany | €475.06K |
|
EVRAZ plc
LSE:EVR
|
UK | GBX7.64 Billion |
|
Sotherly Hotels Inc Series B Pref
NASDAQ:SOHOB
|
USA | $374.63 Million |
|
MagForce AG
STU:MF6
|
Germany | €35.99 Million |
|
Akoustis Technologies, Inc.
NASDAQ:AKTSQ
|
USA | $122.59 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down QuiaPEG Pharmaceuticals Holding AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see QUIA company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how QuiaPEG Pharmaceuticals Holding AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for QuiaPEG Pharmaceuticals Holding AB (2008–2024)
The table below shows the annual total liabilities of QuiaPEG Pharmaceuticals Holding AB from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr6.39 Million ≈ $688.20K |
-76.06% |
| 2023-12-31 | Skr26.71 Million ≈ $2.87 Million |
+27.00% |
| 2022-12-31 | Skr21.03 Million ≈ $2.26 Million |
-11.42% |
| 2021-12-31 | Skr23.74 Million ≈ $2.56 Million |
+15.98% |
| 2020-12-31 | Skr20.47 Million ≈ $2.20 Million |
-13.92% |
| 2019-12-31 | Skr23.78 Million ≈ $2.56 Million |
+170.78% |
| 2018-12-31 | Skr8.78 Million ≈ $945.08K |
+31.35% |
| 2017-12-31 | Skr6.69 Million ≈ $719.52K |
+83.23% |
| 2016-12-31 | Skr3.65 Million ≈ $392.69K |
+86.27% |
| 2015-12-31 | Skr1.96 Million ≈ $210.82K |
-49.63% |
| 2014-12-31 | Skr3.89 Million ≈ $418.52K |
-8.52% |
| 2013-12-31 | Skr4.25 Million ≈ $457.48K |
-44.84% |
| 2012-12-31 | Skr7.71 Million ≈ $829.40K |
+127.08% |
| 2011-12-31 | Skr3.39 Million ≈ $365.25K |
+25.38% |
| 2010-12-31 | Skr2.71 Million ≈ $291.32K |
-4.98% |
| 2009-12-31 | Skr2.85 Million ≈ $306.60K |
-17.66% |
| 2008-12-31 | Skr3.46 Million ≈ $372.35K |
-- |
About QuiaPEG Pharmaceuticals Holding AB
Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as… Read more